Stella Diagnostics (Stella Diagnostics) Short-Term Debt : $0.65 Mil (As of Sep. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Stella Diagnostics Short-Term Debt?

Stella Diagnostics's Short-Term Debt for the quarter that ended in Sep. 2023 was $0.65 Mil.

Stella Diagnostics's quarterly Short-Term Debt stayed the same from . 20 ($0.00 Mil) to Sep. 2022 ($0.00 Mil) but then increased from Sep. 2022 ($0.00 Mil) to Sep. 2023 ($0.65 Mil).

Stella Diagnostics Short-Term Debt Historical Data

The historical data trend for Stella Diagnostics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Stella Diagnostics Short-Term Debt Chart

Stella Diagnostics Annual Data

Trend

Short-Term Debt

Stella Diagnostics Quarterly Data
	Sep22	Sep23
Short-Term Debt	-	0.65

Stella Diagnostics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Stella Diagnostics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Stella Diagnostics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Stella Diagnostics (Stella Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Stella Diagnostics Inc (OTCPK:SLDX) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

50 West Broadway, Suite 300, Salt Lake City, UT, USA, 84104

Website

https://www.stelladx.com

Stella Diagnostics Inc is a molecular diagnostics-based organization focused on improving patient management strategies for people living with severe esophageal disease. It is developing first-line diagnostic tools that provide superior molecular information for providers as compared to the current standard screening protocols.